Cormorant Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Cormorant Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,481,471	Closed	-$37.2M	–	75
2018 Q4	$37.2M	Sell	3,481,471 -75,198	-2%	-$989K	3.02%	10
2018 Q3	$54.3M	Sell	3,556,669 -44,285	-1%	-$645K	3.53%	7
2018 Q2	$44.1M	Hold	3,600,954	–	–	3.26%	7
2018 Q1	$34.4M	Sell	3,600,954 -55,715	-2%	-$601K	2.57%	10
2017 Q4	$33M	Buy	+3,656,669	New	+$26.9M	3.46%	8
2015 Q4	–	Sell	-245,000	Closed	-$2.01M	–	93
2015 Q3	$2.01M	Hold	245,000	–	–	0.32%	62
2015 Q2	$3.42M	Buy	245,000 +75,000	+44%	+$1.38M	0.45%	50
2015 Q1	$4.08M	Sell	170,000 -30,000	-15%	-$675K	0.63%	45
2014 Q4	$3.29M	Buy	+200,000	New	+$2.31M	0.51%	47

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cormorant Asset Management's DRNA Position: Q1 2019 in Review

Cormorant Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2019, closing a stake of 3,481,471 shares — an estimated $37.2M sold.

Cormorant Asset Management first reported a position in DRNA in Q4 2014 and held it in 9 quarters. The position peaked at $54.3M in Q3 2018. 98 funds tracked by Wall St. Rank hold DRNA as of Q1 2019.

Cormorant Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Cormorant Asset Management sold 3,481,471 Dicerna Pharmaceuticals, Inc. shares in Q1 2019, an estimated $37.2M.
Cormorant Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
Cormorant Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $54.3M in Q3 2018.
98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2019.

Based on Cormorant Asset Management's 13F filing for Q1 2019, filed 15 May 2019.